ICON Sets Dates for First-Quarter 2026 Earnings Release and Conference Call
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Icon ( (ICLR) ) has provided an update.
ICON plc announced in Dublin on June 17, 2026 that it will release its financial results for the first quarter of 2026 after the U.S. market closes on Tuesday, June 23, 2026. The company will host a conference call and webcast on Wednesday, June 24, 2026 at 8:00 a.m. ET to discuss its quarterly performance and financial results.
ICON said any changes to the planned earnings events and access to the live webcasts will be provided via the investor section of its website, with a replay available about an hour after the call. The scheduling of the first-quarter earnings release and discussion signals a forthcoming update for investors and other stakeholders on the company’s financial health and operational momentum.
The most recent analyst rating on (ICLR) stock is a Sell
with a $125.00 price target.
To see the full list of analyst forecasts on Icon stock,
see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Neutral.
The score is primarily driven by financial performance that remains generally healthy but shows notable 2025 deterioration in revenue momentum, margins, and cash conversion. Technicals provide a supportive near-term setup (price above key short/mid-term averages with positive MACD), though RSI near 70 and being below the 200-day temper the outlook. Valuation is moderate (P/E ~17.7) but lacks dividend yield support.
To see Spark’s full report on ICLR stock,
click here.
More about Icon
ICON plc is a world-leading clinical research organization headquartered in Dublin, Ireland, providing integrated consulting, clinical development, commercialization and post-marketing solutions. The company supports pharmaceutical, biotechnology, medical device, government and public health clients worldwide and employed about 40,100 people across 97 locations in 55 countries as of December 31, 2025.
Leveraging deep operational and medical expertise, ICON focuses on accelerating innovation from molecule to medicine to improve patient outcomes globally. Its broad geographic footprint and diversified customer base position the company as a key partner in the development and commercialization of emerging therapies.
Average Trading Volume: 1,144,715
Technical Sentiment Signal: Hold
Current Market Cap: $11.31B
Find detailed analytics on ICLR stock on TipRanks’ Stock Analysis page.
